$5.63
+2.18%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$5.75
From 52W high−53.04%
Volume6748.00
Market cap$533.86M
P/E (TTM)—
P/S (TTM)3.3x
Div yield—
Key dataNov 4, 2026
Open
$5.75
From 52W high
−53.04%
Volume
6748.00
Market cap
$533.86M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.1x
P/E (TTM)
—
RSI (14)
50.6
MomentumView details →
1D Return
+2.18%
YTD Return
−34.86%
SummaryUpdated Jun 1, 2026
Valneva SE (NASDAQ:VALN) is a French specialty vaccine company founded in 1998 and headquartered in Saint-Herblain, France. The company went public on NASDAQ in May 2021, having previously traded on European exchanges. Valneva focuses on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs, particularly targeting travel-related and emerging infectious diseases. The company has evolved from a pure research and development organization into a commercial-stage biotechnology company with marketed products and a robust pipeline of vaccine candidates in various stages of clinical development.
Similar companies
Latest newsMore news →
Valneva SE announced that it will report its nine-month 2026 financial results on November 24, 2026.8h agoFrench pharmaceutical stocks Genfit, Nanobiotix and Valneva SE fell between 4.8% and 6.2%.28d agoThe United Kingdom’s Medicines and Healthcare products Regulatory Agency revoked Valneva’s marketing authorization for IXCHIQ following a benefit-risk assessment by the Commission on Human Medicines.28d ago